BRPI0920492A2 - uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. - Google Patents

uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.

Info

Publication number
BRPI0920492A2
BRPI0920492A2 BRPI0920492A BRPI0920492A BRPI0920492A2 BR PI0920492 A2 BRPI0920492 A2 BR PI0920492A2 BR PI0920492 A BRPI0920492 A BR PI0920492A BR PI0920492 A BRPI0920492 A BR PI0920492A BR PI0920492 A2 BRPI0920492 A2 BR PI0920492A2
Authority
BR
Brazil
Prior art keywords
iron
deferiprone
prevention
treatment
eye
Prior art date
Application number
BRPI0920492A
Other languages
English (en)
Inventor
Lawrence Dunaief Joshua
Spino Michael
Original Assignee
Lawrence Dunaief Joshua
Spino Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence Dunaief Joshua, Spino Michael filed Critical Lawrence Dunaief Joshua
Publication of BRPI0920492A2 publication Critical patent/BRPI0920492A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

aplicação de deferiprona para tratamento e prevenção de distúrbios oculares relacionados a ferro. é fornecida aplicação de deferiprona oralmente disponível ou aplicada topicamente para prevenção de lesão ocular induzida por ferro. a aplicação pode ser para preparação de um medicamento ou em um método de prevenção de lesão ocular induzida por ferro a um olho de um paciente em risco para lesão ocular induzida por ferro, o método compreendendo a administração de uma quantidade profilaticamente efetiva de deferiprona ao paciente. é também fornecida a aplicação de deferiprona para tratamento de lesões oculares relacionadas a ferro. a aplicação pode ser para preparação de um medicamento ou em um método de tratamento de lesão a um olho tendo lesão ocular associada com ferro, o método compreendendo a administração de maneira tópica de uma quantidade terapeuticamente efetiva de deferiprona ao paciente.
BRPI0920492A 2009-01-26 2009-11-12 uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro. BRPI0920492A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (en) 2009-01-26 2009-11-12 Use of deferiprone for treatment and prevention of iron-related eye disorders

Publications (1)

Publication Number Publication Date
BRPI0920492A2 true BRPI0920492A2 (pt) 2019-07-09

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920492A BRPI0920492A2 (pt) 2009-01-26 2009-11-12 uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.

Country Status (24)

Country Link
US (1) US20130023569A1 (pt)
EP (1) EP2389179A4 (pt)
JP (1) JP5604631B2 (pt)
KR (1) KR20120078667A (pt)
CN (1) CN102348456A (pt)
AP (1) AP2011005843A0 (pt)
AU (1) AU2009338093B2 (pt)
BR (1) BRPI0920492A2 (pt)
CA (1) CA2750599A1 (pt)
CL (1) CL2011001812A1 (pt)
CR (1) CR20110456A (pt)
EA (1) EA201170970A1 (pt)
IL (1) IL214291A (pt)
MA (1) MA33090B1 (pt)
MX (1) MX2011007947A (pt)
MY (1) MY161269A (pt)
NI (1) NI201100148A (pt)
NZ (1) NZ594728A (pt)
PE (1) PE20120515A1 (pt)
SG (1) SG173145A1 (pt)
TN (1) TN2011000366A1 (pt)
UA (1) UA103366C2 (pt)
WO (1) WO2010083582A1 (pt)
ZA (1) ZA201105514B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11517540B2 (en) 2015-01-09 2022-12-06 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
CA3077514C (en) 2017-10-25 2022-10-11 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
CA2505476C (en) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US20040225004A1 (en) * 2003-02-06 2004-11-11 Bioresponse, Llc Combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
DK1991225T3 (da) * 2006-02-22 2013-12-16 Apotex Technologies Inc Anvendelse af deferipron og fremgangsmåder til at behandle og/eller forebygge Friedreichs ataksi, der resulterer af intracellulær fejlhåndtering af jern
WO2007118276A1 (en) 2006-04-14 2007-10-25 Prana Biotechnology Ltd Method of treatment of age-related macular degeneration(amd)
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
SG173145A1 (en) 2011-08-29
CN102348456A (zh) 2012-02-08
WO2010083582A1 (en) 2010-07-29
AU2009338093A1 (en) 2011-09-08
ZA201105514B (en) 2012-10-31
IL214291A (en) 2015-03-31
MY161269A (en) 2017-04-14
TN2011000366A1 (en) 2013-03-27
EP2389179A4 (en) 2012-08-29
CL2011001812A1 (es) 2012-02-03
US20130023569A1 (en) 2013-01-24
MA33090B1 (fr) 2012-03-01
NZ594728A (en) 2013-03-28
CR20110456A (es) 2012-05-31
JP5604631B2 (ja) 2014-10-08
MX2011007947A (es) 2011-12-14
CA2750599A1 (en) 2010-07-29
EP2389179A1 (en) 2011-11-30
JP2012515725A (ja) 2012-07-12
KR20120078667A (ko) 2012-07-10
IL214291A0 (en) 2011-09-27
PE20120515A1 (es) 2012-05-20
AU2009338093B2 (en) 2014-08-28
AP2011005843A0 (en) 2011-08-31
UA103366C2 (ru) 2013-10-10
EA201170970A1 (ru) 2012-03-30
NI201100148A (es) 2012-03-06

Similar Documents

Publication Publication Date Title
BR112015001158A2 (pt) formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia
BR112017024934A2 (pt) composições farmacêuticas tópicas
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2006108424A3 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
HRP20120798T1 (hr) Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
RU2013123796A (ru) Способ лечения болезни дюпюитрена
WO2007023072A3 (en) Use of ambroxol for the treatment of rhinovirus infections
BRPI0920492A2 (pt) uso de deferiprona para o tratamento e prevenção de doenças oftalmológicas relacionadas ao ferro.
JP6842794B2 (ja) 皮膚外用製剤
BR0107960A (pt) Tratamento de condições alérgicas e inflamatórias
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
BR0318360A (pt) aporfina e oxoaporfina e o uso médico das mesmas
Masmoei et al. The comparison of burn injury (second degree) recovery using silver sulphadiazine ointment 1% and the combination of mastic gum with ghee
BR0017367A (pt) Uso de melagatran ou de um seu derivado farmaceuticamente aceitável, método de tratamento de um distúrbio isquêmico em um paciente tendo, ou sob risco de ter, fibrilação atrial não-valvular, e, formulação farmacêutica
BR112018072164A2 (pt) composição farmacêutica, método para tratamento e/ou prevenção de uma doença de pele de um paciente e/ou para alívio dos sintomas da mesma, e, uso cosmético de uma composição
BR112021024744A2 (pt) Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington
WO2009016379A3 (en) Nr4a agonists ( 6-mercaptopurine) for inhibition of non-ocular scarring
Kuznetsova et al. Treatment of mixed skin infections
AU2012244095A1 (en) Method for the non-surgical treatment of lipodystrophy in a retrovirus-infected individual

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]